BioKangtai established in 1992, focusing on the R&D, production and distribution of human preventive vaccines, listed on the Shenzhen Stock Exchange on February 7, 2017 (stock code:300601), also is the first listed vaccine enterprise in South China. As one of the largest private vaccines manufacturers in China, BioKangtai owns 5 vaccine centers across 2 major cities: 3 centers in Shenzhen and 2 centers in Beijing, offering sufficient production and innovation capacity, the marketing and distribution network covers 31 provinces (autonomous regions and municipalities) in China. Since establishment over 30 years, BioKangtai has developed into a high-tech enterprise with great R&D varieties, ric...
